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Cytoreductive surgery and chemotherapy continue to be the mainstay of ovarian cancer treatment. However, as mortality
from advanced ovarian cancer remains very high, novel therapies are required to be integrated into existing treatment regi-
mens. Immunotherapy represents an alternative and rational therapeutic approach for ovarian cancer based on a body of
evidence supporting a protective role of the immune system against these cancers, and on the clinical success of im-
munotherapy in other malignancies. Whether or not immunotherapy will have a role in the future management of ovarian
cancer is too early to tell, but research in this ﬁeld is active. This review will discuss recent clinical developments of
selected immunotherapies for ovarian cancer which fulﬁl the following criteria: (i) they are antibody-based, (ii) target a dis-
tinct immunological pathway, and (iii) have reached the clinical trial stage. Speciﬁcally, the focus is on Catumaxomab
*Correspondence to: Prof V. A. Heinzelmann-Schwarz, Department of Biomedicine,
University Hospital Basel, Hebelstrasse 20, Basel CH-4031, Switzerland. Tel: +41-79-
793-07-13; Fax: +41-61-265-93-99; E-mail: viola.heinzelmann@usb.ch
© The Author 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oup.com.
reviews Annals of Oncology
(anti-EpCAM × anti-CD3), Abagovomab, Oregovomab (anti-CA125), Daclizumab (anti-CD25), Ipilimumab (anti-CTLA-4),
and MXD-1105 (anti-PD-L1). Catumaxomab has reached phase III clinical trials and exhibits promise with reports,
showing that it can cause a signiﬁcant and sustained reduction in ascites. Phase I–III clinical trials continue to be con-
ducted on the other antibodies, some of which have had encouraging reports. We will also provide our perspective on the
future of immunotherapy for ovarian cancer, and how it may be best employed in treatment regimens.
Key words: antibody, clinical trials, diagnosis, gynaecological cancers, immunology, treatment regimens
introduction
Epithelial ovarian cancer is the ﬁfth most common malignancy in
women and the second leading cause of gynaecological cancer
death worldwide [1]. The majority of patients are diagnosed at an
advanced FIGO stage due to limited screening tools and the non-
speciﬁc nature of symptoms. The 5-year survival rate for women
with early pelvic disease is over 70% but less than 30% for those
with advanced metastatic disease [2]. Ovarian carcinomas are
histologically categorized into serous (75%), mucinous (10%),
endometrioid (10%), clear cell (1%), and undifferentiated (1%)
subtypes. Maximal cytoreductive therapy and chemotherapy (car-
boplatin (Hospira Australia Pty Ltd., Mulgrave, Australia) and
paclitaxel (Bristol-Myers-Squibb, Mulgrave, Australia)) are the two
mainstays of adjuvant therapy, but ∼70% of patients with advanced
disease will relapse despite response to initial treatments [3].
cancer immunotherapy
Immunotherapy represents an alternative and rational approach
for the treatment of cancer, including ovarian cancer. A major
function of the immune system is to continually seek out and
eliminate cancer cells as they arise in a process described as
cancer immunosurveillance [4]. This involves both innate and
adaptive immune mechanisms that function complimentarily to
promote tumour immunity (supplementary 1, available at
Annals of Oncology online). Most importantly is that anti-tumour
immune responses can be induced by immunological agents.
Various forms of immunotherapies (passive and active) are
central components of treatment regimens for a number of malig-
nancies [5]. Several lines of clinical evidence collectively suggest
that the immune system is protective against ovarian cancer, and
thus forms the basis of immunotherapy for this disease (supple-
mentary 2, available at Annals of Oncology online).
antibodies as therapeutic agents
for cancer
Antibodies are glycoproteins composed of two heavy chains and
two light chains joined by disulphide bonds, with the antigen-
binding site located at the C-terminus and the constant region
at the N-terminus. Antibodies are excellent anti-cancer agents
by virtue of their high speciﬁcity for antigen, stability, and sim-
plicity to be mass-produced by bioengineering technology. As
therapeutic molecules, they can exist in various formats: fully
mouse, chimeric [murine variable regions fused to the constant
region (Fc) of the human antibody], humanized (murine com-
plementarity determining regions fused to the human antibody
backbone), or fully human [6]. Antibodies can potentially
induce tumour cell apoptosis via a number of mechanisms: (i)
complement-dependent cytotoxicity (CDC) is initiated when
the Fc portion of immunoglobulins (Igs) activates the comple-
ment system, leading to the assembly of the membrane attack
complex, which disrupts the plasma membrane causing cell
lysis [7]. (ii) Antibody-dependent cellular cytotoxicity (ADCC)
involves the cross-linking of the Fc domain of antigen-bound Ig
(usually IgG1 or IgG3) with Fcγ receptors (FcγRs), such as
FcγRIIIA (CD16A) on natural killer (NK) cells, promoting the
release of perforin and granzymes that mediate lysis of tumour
cells [8]. (iii) Antibodies can also indirectly induce tumour cell
death through modulation of anti-tumour immunity via block-
ade of immune-checkpoint inhibitors. By targeting regulatory
molecules on immune cells that would normally dampen their
activity [e.g. programmed cell death 1 protein (PD-1)], more
robust and durable anti-tumour immune responses could result.
(iv) Antibodies can also limit tumour growth by binding to
growth receptors, preventing interactions with endogenous
ligands, and hence inhibiting downstream signalling events.
This review will review recent developments in various anti-
body-based immunotherapies undergoing clinical trials for
ovarian cancer. The discussed anti-cancer agents fulﬁl the fol-
lowing criteria: (i) they are antibody-based, (ii) target various
immunological pathways (in order to highlight the broad spec-
trum of strategies used in the ﬁeld), and (iii) have reached the
clinical trial level (Table 1).
catumaxomab
The human epithelial cell adhesion molecule (EpCAM) is a
Type I transmembrane glycoprotein frequently expressed on a
variety of cancer types, including ovarian, gastric, prostate, and
breast cancers [9–11]. It is either expressed at very low levels or not
at all on normal ovarian surface epithelium [12], but is frequently
over-expressed in ovarian cancers of serous (68%), endometrioid
(82%), clear cell (92%), and mucinous (49%) histological subtypes,
and over-expression correlates with lower overall survival (OS) [10].
Over 90% of ovarian cancer patients have EpCAM over-expressed
on tumour cells present in ascites [13]. Pathophysiologically,
EpCAM has been reported to impact on tumour cell proliferation
by upregulating the oncogene c-myc [14] and to dampen anti-
tumour immunity by blocking antigen presentation on dendritic
cells [15]. Therefore, EpCAM has attracted much interest as a target
in cancer immunotherapies.
Catumaxomab (Removab) is a monoclonal bispeciﬁc anti-
body approved in 2009 in the European Union for the intraperi-
toneal treatment of patients with malignant ascites. The
antibody has two different antigen-binding sites: one for human
EpCAM (via a heavy and light chain of a rat IgG2b antibody)
and another for human CD3 (via a heavy and light chain of a
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Table 1. Clinical trials of selected antibody-based immunotherapies for ovarian cancer
Immunotherapies in phase I–III trials
Drug Proposed mode of
action
Antibody Target antigen Phase Indication No. of patients Clinical notes Ref.
Catumaxomab Trifunctional bi-
speciﬁc antibody
Non-humanized
chimeric rat IgG2b/
mouse IgG2a
EpCAM I/II Recurrent ascites due to
progressive chemo-
resistance
23 Reduced ascites volume and number
of EpCAM+ in ascites
[26]
II/III Malignant ascites secondary
to epithelial
adenocarcinomas
258 (129 ovarian) Treatment associated with longer
median puncture-free survival and
median time to next paracentesis
[27]
Abagovomab Anti-idiotypic vaccine Murine IgG1k CA-125 I FIGO stage III and IV ovarian
cancer
42 Increased number of CA-125 speciﬁc
CD8+ T cells in some patients
[35]
I FIGO stage I–IV ovarian
cancer
36 Increased number of CA-125 speciﬁc
CD8+ T cells in some patients
[36]
Ib/II Ovarian, tubal and peritoneal
cancers
119 68.1% patients developed Ab3
responses, correlating with
longer OS
[37]
III Ovarian cancer 888 Results pending [38]
Oregovomab Activation of idiotypic
network
Murine IgG1 CA-125 II FIGO stage I–IV ovarian
cancer
20 Increased T-cell responses to CA-125
and autologous tumour cells in
some patients, correlating with
longer survival
[42]
II Recurrent ovarian, tubal, and
peritoneal adenocarcinoma
13 No overt reduction in tumour burden [44]
Not speciﬁed FIGO stage I–IV ovarian
cancer
184 Development of anti CA-125
antibody (Ab3) responses in some
patients
[41]
Not speciﬁed FIGO stage I–IV ovarian
cancer
75 Development of Ab2 and Ab3 levels
in some patients. Evidence that
Ab3 mediates ADCC in some
patients
[43]
Not speciﬁed FIGO stage I–IV ovarian
cancer
49 Development of Ab2 and Ab3 levels
in some patients, correlating with
survival advantage
[40]
III FIGO stage III and IV 375 Oregovomab as a mono-
immunotherapy did not improve
clinical outcomes
[45]
Daclizumab Anti-regulatory T cell Humanized IgG1 CD25 Not speciﬁed Not speciﬁed Not speciﬁed Results pending [60]
Ontak Anti-regulatory T cell N/A (fusion protein of
IL-2 and diphtheria
toxin)
CD25 I/II Advanced cancer 4 (2 ovarian) Treatment associated with reduction
in regulatory T-cell numbers.
Signiﬁcant drop in CA-125 levels
in one patient
[55, 63]

|Tse
etal.
Volum
e
25
|N
o.2
|February
2014
review
s
A
nnals
ofO
ncology
mouse IgG2a). It also contains a functional Fc region that binds
to activating receptors on accessory cells (macrophages, dendrit-
ic cells, and NK cells) for immunological effector function. The
rationale of using Catumaxomab is to activate and recruit T cells
to EpCAM-expressing tumours while simultaneously stimulating
accessory cells via their FcγRs. The result is tumour cell destruc-
tion by ADCC and/or T-cell-mediated cytotoxicity via perforin
and granzyme B [16].
In a phase I/II clinical trial involving 23 ovarian cancer
patients with recurrent ascites due to progressive chemo-resist-
ant disease, treatment with Catumaxomab resulted in a signiﬁ-
cant and sustained reduction in ascites [17]. Catumaxomab
substantially reduced the number of EpCAM-positive tumour
cells within ascites by up to 5 log, with six patients even showing
negative cytology. A recently completed phase II/III clinical trial
compared the efﬁcacy of Catumaxomab plus paracentesis
(C + P) to paracentesis alone (P) in 258 patients with recurrent
chemo-resistant adenocarcinoma (ovarian, gastric, breast, pan-
creas, colon, and endometrial) presenting with ascites [18]. In
the ovarian cancer arm, the median puncture-free survival,
deﬁned as the time after treatment (Day 0) to the ﬁrst need for
paracentesis, was 52 days for C + P versus 11 days for P alone
(P < 0.0001). This suggests that Catumaxomab functions rela-
tively rapidly to alleviate ascites accumulation. Similarly, the
median time to next paracentesis was signiﬁcantly longer in the
C + P group (71 versus 11 days) (P < 0.0001). This represented a
six- to seven-fold prolongation and would be highly beneﬁcial
to patients since ascites has a high morbidity and repeated para-
centesis increases the risk of infection, bowel perforation, and
adhesions. Catumaxomab was also shown to increase the ratio
of CD45+ cells (immune cells) to EpCAM-positive tumour cells
in ascites throughout the course of treatment, with some
patients having EpCAM-positive cells no longer detectable.
Since Catumaxomab is composed of antibody chains of mouse
and rat origin, it is expected that human anti-mouse antibodies
(HAMAs) will be induced when administered to patients.
Indeed, Catumaxomab induced greater clinical beneﬁts for
patients who developed HAMAs [19]. In ovarian cancer patients,
the median puncture-free survival was 64 versus 30 days for
HAMA-positive/-negative responders, respectively. The median
time to next puncture was 104 versus 32 days, and OS was 163
compared with 82 days. From these clinical trial outcomes,
Catumaxomab appears to be a promising immunotherapy for
ovarian cancer and may be particularly useful for patients pre-
senting with chemotherapy-resistant disease with recurrent
ascites. Although some immunotherapy can be compromised by
the HAMA response, it can sometimes augment the therapeutic
response. In these studies, Catumaxomab was generally well
tolerated with most common adverse events being reversible
mild-to-moderate nausea and abdominal pain.
abagovomab and oregovomab
Antibodies can function as antigens in the form of ‘anti-idioty-
pic antibodies’. Immunization with a given antigen (x) results in
the generation of anti-x antibodies, which can be referred to as
Ab1 [20]. Neils Jerne proposed that these antibodies may them-
selves be immunogenic and deﬁned the immunogenic determi-
nants of the antibody as idiotopes. The idiotopes of Ab1 can
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function as antigen that evokes the generation of antibodies
(anti-idiotypic). Ab2 are antibodies that result from exposure
to Ab1, some of which are anti-idiotypic. Since idiotopes are con-
centrated in the highly variable region of the antigen-binding
site, some Ab2 will have idiotopes that effectively mimic the
three-dimensional structure of antigen x. Experimental evidence
suggests that, in some circumstances, exposure to Ab2 may pro-
voke a more effective response than exposure to antigen. These
antibodies, in turn, may stimulate the production of Ab3, some of
which target the idiotopes of Ab2, and bind to antigen x.
CA125 is a high-molecular-weight mucin-like glycoprotein
over-expressed on the surface of ovarian cancer cells. It is also
shed into the bloodstream and is currently the most widely used
tumour marker for ovarian cancer. A high level of serum CA125
at ovarian cancer diagnosis frequently indicates widespread
peritoneal dissemination, and a continual increase in its value
generally indicates disease progression and/or relapse [21, 22].
Although CA125 is in clinical use as a tumour marker, its bio-
logical function is still poorly understood; some studies suggest
that it is involved in cell adhesion, migration, and invasion, and
may have immunosuppressive properties [23, 24]. CA125 binds
with high afﬁnity to mesothelin, a protein highly expressed on
the surface of the peritoneal lining [23]. The human serous
ovarian cancer cell line OVCAR-3 (CA125-proﬁcient) adheres
strongly to mesothelin-expressing cells but not when CA125
was silenced through siRNA, suggesting that CA125 may con-
tribute to peritoneal metastasis at some levels. CA125 knock-
down was shown in ovarian cancer cell lines to reduce their
motility and invasiveness (associated with matrix metalloprotei-
nase-2 down-regulation) and to suppress their growth by induc-
tion of caspase-dependent apoptosis [25]. In another study,
incubation of NK cells with CA125 decreased their cytolytic ac-
tivity against target cells by 50%–70%, suggesting that CA125
exhibits immune suppressive properties as well [24].
Abagovomab (ACA-126) is a murine IgG1k monoclonal anti-
body (Ab2) with its idiotope imitating CA125 and is currently
being investigated as an anti-idiotypic vaccine for ovarian
cancer. In a phase I trial involving 42 patients with chemother-
apy-resistant ovarian cancers (93% with FIGO stages III–IV;
67% serous histotype), Abagovomab induced Ab3 and HAMA
responses in all patients [26]. Moreover, 5 of 5 patients also had
detectable CA125-speciﬁc interferon (IFN)-γ-producing T cells
post vaccination, whereas none were detectable in any subjects
before treatment. Abagovomab also strongly increased serum
levels of IFN-γ, which indicates the induction of Th1 immune
responses, in a subset of 25 patients. In another phase I clinical
trial involving 36 patients with similar clinicopathological
characteristics, a two-fold increase in the number of CA125-
speciﬁc CD8+ T cells was found in those that received nine
(75%) injections of Abagovomab compared with those with six
(17.6%) injections, suggesting that the strength of the immune re-
sponse is dose-dependent [27]. A phase Ib/II clinical trial with
119 patients with CA125-positive ovarian, tubal, or peritoneal
cancers showed that 68.1% of patients that received Abagovomab
developed Ab3 responses [28]. Strikingly, Ab3 responders had a
signiﬁcantly longer OS (23.4 months) compared with Ab3 non-
responders (4 months) (P < 0.0001). When the patient cohort
was stratiﬁed for FIGO stage, type of ﬁrst-line chemotherapy, and
the number of previous therapies, the trend of longer survival in
Ab3 responders was maintained. ADCC was also observed in
some patients (26.9%) and they had signiﬁcantly longer median
survival than those that did not (25 versus 10 months;
P = 0.0126), suggesting that ADCC may be a mechanism that
mediates the anti-tumour effect of Abagovomab. In these clinical
trials, the drug was generally well tolerated with common side-
effects including local reactions at the injection site and fatigue.
Such promising data have resulted in the initiation of a rando-
mized, double-blind, placebo-controlled phase III trial involving
888 patients with FIGO stage III/IV ovarian cancer known as
‘Monoclonal antibody Immunotherapy for Malignancies of
Ovary by Subcutaneous Abagovomab’ (MIMOSA) trial [29].
While Abagovomab was shown to be safe and induced measur-
able immune responses, the study concluded that when the anti-
body was employed as a maintenance therapy for patients with
ﬁrst remission, it did not prolong relapse-free and OS [30].
Oregovomab (B43.13, OvRex) is a murine monoclonal antibody
of IgG1 subclass with high afﬁnity for CA125 (KD = 1.2 × 10
10
M−1). It was initially developed as a Technetium 99c-labelled anti-
body for the immunoscintigraphic detection of recurrent ovarian
cancer by virtue of their expression of CA125 [31]. However,
some patients that received this tumour-imaging agent had an un-
expected survival advantage, prompting investigations into the
antibody’s potential as a therapy for ovarian cancer. Oregovomab
does not directly inhibit tumour growth nor does it induce CDC
or ADCC by itself. However, it elicits tumour-speciﬁc, T-cell
responses. Noteworthy, anti-CA125 antibodies evoked from
Oregovomab treatment are not necessarily Ab3. Other mechan-
isms such as the formation of immunostimulating complexes may
also lead to the generation of anti-CA125 antibodies.
In a trial involving 184 patients with ovarian cancer (FIGO
stages I–IV), a single treatment of Oregovomab caused a rapid
reduction in serum levels of CA125 due to the formation of
immune complexes [32]. After multiple treatments (1–10 infu-
sions), 26 of 60 (43%) patients had a greater than three-fold in-
crease in anti-CA125 antibody levels, and the level of increase
correlated with the amount of circulating CA125 at the time of
injection. Anti-CA125 antibody responders also had longer sur-
vival times compared with non-responders (22.9 versus 13.5
months; P = 0.0089). In addition, 9 of 17 (53%) patients showed
an increase in T-cell proliferation in response to CA125 and had
signiﬁcantly longer survival time than non-responders (>84
versus 13.2 months; P = 0.0202). These ﬁndings suggest that
generation of humoural and cellular anti-CA125 responses con-
tribute to the clinical beneﬁts of Oregovomab treatment.
Similarly, in a phase II trial which recruited 20 patients with
platinum-resistant recurrent ovarian cancer (FIGO stages I–IV),
Oregovomab increased T-cell responses to CA125 in 7 of 18
(39%) patients and to autologous tumour cells in 5 of 8 (63%)
[33]. Patients who developed a T-cell response to CA125 and/or
autologous tumours also had longer survival compared with
non-responders (median not reached versus 51.9 weeks). In
another trial involving 75 patients with ovarian cancer (FIGO
stages I–IV) treated with Oregovomab (1–10 infusions), 48
(64%) developed Ab2 antibodies, and 18 (24%) developed anti-
CA125 antibodies [34]. Incubation of OVCAR3-NU3 cells with
anti-CA125 antibodies puriﬁed from the serum of these patients
in the presence of peripheral blood mononuclear cells led to ef-
fective lysis of tumour cells, indicating that ADCC was
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operative. However, these antibodies did not mediate killing of
tumour cells via CDC in the study. In a retrospective analysis of
a previous trial including 44 patients with recurrent ovarian
cancer (majority being FIGO stages III–IV), treatment with
Oregovomab resulted in the development of HAMA in 27 of
40 (67.5%) patients, anti-idiotypic antibodies (Ab2) in 76.7%
of patients, and an increase by more than three-fold in the level
of anti-CA125 antibodies in 28% of patients [31]. The ability of
patients to generate these idiotypic network-related antibodies
also correlated with a survival advantage; median survival for
HAMA responders was 22.6 versus 7.2 months for non-responders
(P = 0.0016). Similarly, for Ab2 responders and non-responders,
the median survival was 18.3 versus 9.3 months (P = 0.075), and
for anti-CA125 responders versus non-responders, 18.2 versus
13.1 months (P = 0.0896). However, such clinical beneﬁts of
Oregovomab were not demonstrable in one pilot phase II study.
No overt reduction in tumour burden was observed in any of
the 13 patients treated with Oregovomab, despite most having
measurable T- and B-cell responses [35]. Similarly, a phase III
trial which recruited 375 ovarian cancer patients with FIGO
stage III and IV showed that while bioactivity was demonstrable
and the drug was well tolerated, patients receiving Oregovomab
as a mono-immunotherapy had similar clinical outcomes as
those given placebo [36]. Recently, the therapeutic potential of
combining Oregovomab with conventional chemotherapies,
carboplatin and paclitaxel, were investigated in a phase II clinic-
al trial [37]. In that study, 40 patients with FIGO stages III/IV
were split into two groups and received Oregovomab either sim-
ultaneously or 1 week after carboplatin–paclitaxel treatment.
Although the main objectives of that trial were to compare the
magnitude of antibody and cellular responses to CA125 evoked
by the two treatment schedules, the authors concluded that the
immune responses triggered by this chemo-immunotherapy
were stronger than those measured in previously published
mono-immunotherapy protocols.
daclizumab and ontak
Regulatory T cells (Tregs) are a subset of T cells that mediate
immune suppression and are involved in the prevention of auto-
immunity [38]. They inhibit the proliferation, cytokine produc-
tion, and cytotoxicity of Th1 T cells, CD8+ T cells, and NK cells
via cell–cell contact and the secretion of immunosuppressive
factors [39–42]. Regulatory T cells also suppress immune activa-
tion by down-regulating co-stimulatory molecules that are ne-
cessary for T-cell activation on dendritic cells [43].
Early studies reported that regulatory T cells were CD4+ and
CD25+; CD25 is the interleukin (IL)-2 receptor α chain [44,
45]. However, the best current marker of regulatory T cells is the
transcription factor ‘foxhead box P3 (foxp3)’. Importantly,
CD25 is not a speciﬁc marker of regulatory T cells as it is also
expressed on activated effector T cells. One study reported that
malignant ascites from previously untreated ovarian cancer
patients contained signiﬁcant numbers of CD4+ CD25+ CD3+
T cells, whereas these cells were rarely seen in non-malignant
ascites [46]. FIGO stages III–IV ovarian cancers were also
shown to be more abundant with CD4+ CD25+ cells than stages
I–II tumours [46]. Moreover, higher tumour inﬁltration of regu-
latory T cells correlated with shorter patient survival [47, 48],
suggesting that regulatory T cells may facilitate ovarian cancer
progression. Therefore, strategies that block or transiently
deplete these cells may prove useful in treating cancer patients.
This is supported by animal studies, whereby systemic removal
of CD25+ cells with a cell-depleting monoclonal antibody can
elicit potent and durable anti-tumour responses [49, 50].
Daclizumab (Zenapax) is a cell-depleting humanized IgG1
monoclonal antibody speciﬁc for CD25. It is currently being
evaluated in clinical trials as an immunotherapy for a variety of
cancers, including ovarian cancer [51]. Although results from
clinical trials of Daclizumab in ovarian cancer have yet to be
released, data from clinical trials of Ontak (Denileukin Diftitox),
another form of CD25-targeted therapy, are encouraging. Ontak
is an engineered protein combining IL-2 with diphtheria toxin
causing apoptosis of CD25+ cells. It is FDA-approved for the
treatment of cutaneous T-cell leukaemia and currently being
investigated as a therapy for other cancer types, including meta-
static ovarian, renal [52], and breast cancers [53]. In a phase I/II
clinical trial involving seven patients with advanced adenocar-
cinomas, including ovarian cancers, treatment with Ontak was
associated with a reduction in peripheral blood CD3+ CD4+
CD25+ cells and an increase in the number of circulating IFN-
γ-producing T cells [46]. In one patient with FIGO stage IV
ovarian cancer, blood CA125 dropped from 121–17 units/ml 39
days after her ﬁrst of seven infusions [54]. A positron emission
tomography scan revealed that all lymph node, visceral, and
bone metastases had resolved with the exception of one lesion in
the left groin which had progressed. In all patients, Ontak was
generally well tolerated and further trials are ongoing [54].
ipilimumab
Effective T-cell activation requires two signals, namely (i) inter-
action of the T-cell receptor with antigen in association with
(MHC) molecules, and (ii) co-stimulation of CD28 on T cells
with CD86 and CD80 on antigen-presenting cells (APCs).
A lack of co-stimulatory signals can result in T-cell anergy.
Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is a
homologue of CD28 expressed on the surface of T cells upon ac-
tivation and is a key molecule in the down-regulation of T-cell
activity as a means to limit self-damage. It inhibits the activation
of T cells by effectively outcompeting CD28 for its ligands on
APCs (CTLA-4 has a higher afﬁnity for CD86 and CD80) and/
or delivering inhibitory signals to T cells [55]. In this sense,
CTLA-4 functions as an immune-checkpoint receptor. CTLA-4
is also constitutively expressed on regulatory T cells and is a
mechanism by which they mediate immune suppression [56].
The use of therapeutic agents to block CTLA-4 function pre-
vents immune inactivation and is a rational approach to evoke
effective anti-tumour immune responses.
Ipilimumab (MDX-CTLA-4, Yervoy) is a fully human IgG1
monoclonal antibody, which binds to and blocks the activity of
CTLA-4. It was recently approved by the FDA for the treatment
of advanced melanoma [57]. A phase III clinical trial comprised
of patients with unresectable pre-treated stages III–IV melan-
oma, demonstrated that treatment with Ipilimumab prolonged
the median survival by ∼4 months—the ﬁrst compound shown
to have such beneﬁcial effects in these patients [58]. Results
from several studies suggest that the anti-tumour effect of
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Ipilimumab is mediated by immune modulation. Treatment
with Ipilimumab has been reported to increase (i) absolute
lymphocyte count [59], (ii) expression of inducible co-stimula-
tor (ICOS) on CD4+ T cells [60], and (iii) antibody and T-cell
responses to the cancer-testis antigen NY-ESO-1 [60, 61]. In
most cases, such responses correlated with clinical beneﬁt and
OS. Moreover, in some trials, response rates have been substan-
tially higher in patients who developed immune-related adverse
events such as enterocolitis [62] or hypophysitis [63] than those
who did not. Although the majority of Ipilimumab trials, to
date, have been on melanoma, a few ovarian cancer trials have
been conducted. In a phase I/II trial on 11 patients with FIGO
stage IV ovarian cancers which had previously either received
chemotherapy or GVAX [a vaccine product comprised on au-
tologous, irradiated tumour cells engineered to secrete the
immune stimulatory cytokine, granulocyte macrophage colony-
stimulating factor), Ipilimumab was generally well tolerated
with the exception of some grade 3 inﬂammatory toxicities [64,
65]. Signiﬁcant anti-tumour effects were noted in one particular
ovarian cancer patient who showed a dramatic fall of serum
CA125 levels during treatment with a substantial regression of a
large hepatic metastasis, mesenteric lymph nodes, and an
omental cake [65]. Moreover, generation of antibody responses
to NY-ESO-1 was detectable and this correlated with the
observed therapeutic effects. Another ovarian cancer patient had
a reduction in pain and ascites, which correlated with stabiliza-
tion of CA125 levels. Four other patients had stable disease as
assessed by blood CA125 levels and imaging.
current stage of immunotherapy
in ovarian cancer
It is still unclear if immunotherapy has the potential to be incor-
porated into treatment regimens against ovarian cancer. Over the
past decade, there has been an increase in the number of anti-
body-based immunotherapeutics that have reached the clinical
trial stage. While Catumaxomab, Abagovomab, and Oregovomab
have already reached phase III, many other new antibody-based
treatments have just entered phase I and II clinical trials.
Catumaxomab particularly shows promise and was recently
approved by the European Community for the treatment of ma-
lignant ascites. Results from larger trials of this antibody are
greatly anticipated. Abagovomab and Oregovomab, which
showed promise based on early clinical trials, have largely been
disappointing in recent phase III trials with no overt anti-tumour
efﬁcacy reported. In recent years, immune-checkpoint inhibitors,
such as Ipilimumab, MDX-1105, and MDX-1106, the latter two
targeting the PD-1/PD-L1 axis (supplementary 3, available at
Annals of Oncology online), have emerged as candidates for
cancer immunotherapy [66], although few clinical trials for
ovarian cancer have been conducted so far. For this research ﬁeld
to move forward, it is important to consider the limiting factors
of clinical trials in order to improve the design of future studies.
A limitation common to almost all cancer clinical trials is that
the patients already have advanced disease. This is a major issue
especially for immunotherapy because the ability to initiate an
immune response, or its magnitude, is limited by the extent of
disease burden, the suppressive effect of the tumour
microenvironment, and the multiple layers of immunological
tolerance mechanisms (e.g. regulatory T cells), which keep the
immune response in check. As a consequence, immune-based
therapies are more likely to be effective in patients with low
volume disease such as earlier stage cancers or after cytoreduc-
tive treatment with minimal residual disease.
Realistically, if immunotherapy is to be applied to ovarian
cancer treatment regimens in the short-to-medium term, it
would be as an adjunct therapy rather than as a front-line
monotherapy. Future clinical trials should investigate the syner-
gistic potential of immune-modulating agents with established
chemotherapies. Indeed, Oregovomab was recently investigated
as a combination therapy with standard carboplatin–paclitaxel
in a phase II clinical trial, and stronger immune responses were
measured than those reported in a previous mono-immunother-
apy protocol [37]. Chemo-immunotherapy is appealing not
only because chemotherapies directly induce apoptosis of
tumour cells and result in the release of antigen to drive
immune responses, but they often also disrupt essential immune
regulatory mechanisms that limit the development of immunity,
an increasingly appreciated attribute [67]. Low-dose cyclophos-
phamide and ﬂudarabine have been shown to selectively deplete
and suppress regulatory T-cell activity, rendering tumours cells
more susceptible to immune-mediated cytotoxicity [68, 69]. An
ideal combination of chemo-immunotherapy would be one
where both agents have minimal overlapping toxicities, work via
independent mechanisms but have additive or synergistic anti-
tumour effects. A successful example of this approach is the
combination of ﬂudarabine, cyclophosphamide, and rituximab
(FCR) for chronic lymphocytic leukaemia (CLL). The addition
of rituximab to the chemotherapies increases the rate of com-
plete remission and OS [70]. However, it is critical to optimize
the dosage, sequence, and timing of administering the each drug
as all these parameters could impact on the outcome.
Another point to consider in the design of future clinical
trials is to acknowledge that ovarian cancer is a heterogeneous
disease with four major histological subtypes, each of which
have distinct genetic proﬁles which may affect the ability and/or
magnitude of immune responses evoked by an immunotherapy.
The heterogeneity of ovarian cancer can be further highlighted
by differences in the anti-glycan antibody proﬁles of patients
with various histotypes (supplementary 4, available at Annals of
Oncology online). As a consequence, it is necessary to conduct
clinical trials on more homogenous populations, for example,
serous cancer patients only, to have greater power to detect po-
tential clinical efﬁcacy. Pooling patients into a single cohort may
reduce the sensitivity to detect clinical beneﬁts to certain histo-
types. The importance of stratifying treatment based on histo-
type is supported by recent evidence of contrasting clinical
outcomes in mucinous and serous ovarian cancers when treated
with platinum-based chemotherapy [71]. These two histotypes
may be distinct entities altogether [71], and investigations are
underway to determine how each could be best managed.
An important lesson learnt in recent years is not become
overly excited with novel drugs that show particular promise in
phase I and/or II clinical trials because quite often they fail to
meet the high expectations in phase III studies. This can be
highlighted through Abagovomab, Oregovomab, and more re-
cently Farletuzumab, a humanized IgG1κ antibody that binds to
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folate receptor α (FRα), which is highly expressed on 90% epi-
thelial ovarian cancers but not on normal ovarian tissues [72,
73]. Farletuzumab has been shown to inhibit tumour growth
through CDC, ADCC, and direct anti-proliferative actions, and
a phase I trial reported it to be well tolerated [74]. A phase II
clinical trial involving platinum-sensitive patients experiencing
ﬁrst relapse showed that Farletuzumab in combination with car-
boplatin/taxane improved objective response rates (ORRs) com-
pared with historical controls, and increased duration of second
remission compared with ﬁrst remission in some patients [75].
However, a recent phase III trial using this combination did not
meet the primary end point of progression-free survival (PFS),
and another phase III trial was terminated early due to the lack
of efﬁcacy in interim analyses [76, 77]. Although these results
are rather disappointing, it is important for our research ﬁeld to
not give up on exploring immunotherapy in combination with
chemotherapy because there are glimpses of efﬁcacy in some
patients from initial studies. We need to think critically the
reasons for this, and design future clinical trials accordingly.
conclusion
A wide range of immune-modulating approaches are currently
being evaluated for the treatment of ovarian cancer. As the
results of clinical trials of the discussed antibody-based im-
munotherapies are inconsistent, it is still too early to conclude if
these drugs will be incorporated into treatment regimens against
ovarian cancer. Furthermore, their true potential may lie within
being strategically employed in chemo-immunotherapy regi-
mens.
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Background: Approximately a quarter of men with metastatic non-seminomatous germ cell tumor (NSGCT) have a re-
sidual mass, typically in the retroperitoneum, after chemotherapy. The management of small residual masses (≤1 cm) is
controversial, with good outcomes seen with either post-chemotherapy retroperitoneal lymph node dissection (PC-
RPLND) or surveillance. We sought to review our experience of surveillance and synthesize the cumulative ﬁndings with
the current literature in the form of a meta-analysis.
Patients and methods: We searched PubMed, EMBASE and abstracts from ASCO and AUA to identify relevant,
English-language studies for the meta-analysis. The DFCI (Dana Farber Cancer Institute) database was constructed from
a database of men undergoing cisplatin-based chemotherapy for metastatic NSGCT. The outcomes of interest were the
proportion with necrosis, teratoma or active cancer on histology at PC-RPLND (literature) and the total number of
relapses, RP-only relapses and overall survival in men undergoing surveillance (literature and DFCI cohort).
Results: Three of 47 men undergoing post-chemotherapy surveillance at our institution relapsed over a median follow-
up of 5.4 years. All three were alive at a median of 4.2 years after relapse. On meta-analysis, the pooled estimates of ne-
crosis, teratoma and active cancer in the 588 men who underwent PC-RPLND were 71, 24 and 4%, respectively. Of the
combined 455 men who underwent surveillance, the pooled estimate of the relapse rate was 5%, with an RP-only relapse
rate of 3%. Of the 15 men who suffered an RP-only relapse on surveillance, two died of disease.
Conclusion: Surveillance is a reasonable strategy for men with minimal residual RP disease after chemotherapy and
avoids an RPLND in ∼97% of men who are cured with chemotherapy alone.
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introduction
Testicular cancer is the commonest solid tumor in men aged
between 15 and 34 and notable for the fact that the vast majority of
men with metastatic disease are cured with cisplatin-based chemo-
therapy [1]. However, around 20–25% of patients with non-semino-
matous germ cell tumor (NSGCT) will have a residual tumor mass,
most often in the retroperitoneum (RP) [2]. Surgery, in the form of
post-chemotherapy RP lymph node dissection (PC-RPLND), is
routinely carried out for patients with residual masses greater than
1 cm as ∼45% will harbor teratoma and 10% viable cancer [3–6].
The management of NSGCT with small residual masses (≤1
cm in short axial dimension in accordance with RECIST 1.1)
post-chemotherapy is controversial. Men achieving serologic
and radiologic complete remission are treated with PC-RPLND
at certain institutions as routine policy, with its advantage of
being able to resect potential low volume chemoresistant tera-
toma or viable residual cancer [7]. However, recent reports have
suggested that surveillance may be an option in this situation [8, 9]
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